OM:SPEC

Stock Analysis Report

Executive Summary

SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and reactive drugs.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Share Price & News

How has SpectraCure's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

12.6%

SPEC

4.1%

SE Medical Equipment

2.2%

SE Market


1 Year Return

250.0%

SPEC

38.1%

SE Medical Equipment

16.0%

SE Market

Return vs Industry: SPEC exceeded the Swedish Medical Equipment industry which returned 38.1% over the past year.

Return vs Market: SPEC exceeded the Swedish Market which returned 16% over the past year.


Shareholder returns

SPECIndustryMarket
7 Day12.6%4.1%2.2%
30 Day-13.8%1.6%2.7%
90 Day-15.5%1.6%4.2%
1 Year250.0%250.0%39.6%38.1%21.0%16.0%
3 Year1692.0%1393.3%58.1%39.6%34.5%14.2%
5 Yearn/a67.9%40.1%61.7%27.1%

Price Volatility Vs. Market

How volatile is SpectraCure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SpectraCure undervalued compared to its fair value and its price relative to the market?

28.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SPEC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SPEC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SPEC is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: SPEC is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SPEC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SPEC is overvalued based on its PB Ratio (28.2x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is SpectraCure forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

147.2%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SPEC's forecast earnings growth is above the savings rate (0.4%).

Earnings vs Market: Insufficient data to determine if SPEC's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SPEC is forecast to have no revenue next year.

High Growth Revenue: SPEC is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SPEC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has SpectraCure performed over the past 5 years?

-18.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SPEC is unprofitable, and losses have increased over the past 5 years at a rate of -18% per year.

Accelerating Growth: Unable to compare SPEC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPEC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).


Return on Equity

High ROE: SPEC has a negative Return on Equity (-19.74%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SPEC is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SPEC is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is SpectraCure's financial position?


Financial Position Analysis

Short Term Liabilities: SPEC's short term assets (SEK47.5M) exceeds its short term liabilities (SEK4.0M)

Long Term Liabilities: SPEC has no long term liabilities


Debt to Equity History and Analysis

Debt Level: SPEC is debt free.

Reducing Debt: SPEC has not had any debt for past 5 years.


Balance Sheet

Inventory Level: SPEC has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SPEC's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if SPEC has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SPEC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is SpectraCure's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SPEC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SPEC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SPEC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SPEC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SPEC's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of SpectraCure's salary, the management and board of directors tenure and is there insider trading?


CEO

Masoud Khayyami (56yo)

0yrs

Tenure

0

Dr. Masoud Khayyami, Ph.D. is a Founder and serves as Manager at MK Capital AB. He serves as the Chief Executive Officer at SpectraCure AB. He is a founder and serves as Chief Executive Officer and Head of ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buykr190,78909 Oct 19
MK Capital AB
EntityCompany
Shares10,100
Max Pricekr18.89
Sellkr597,98507 Dec 18
MK Capital AB
EntityCompany
Shares264,595
Max Pricekr2.26
Sellkr138,87907 Dec 18
Masoud Khayyami
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares1,388,787
Max Pricekr0.10
Buykr1,389,12329 Oct 18
Masoud Khayyami
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares264,595
Max Pricekr5.25
Buykr7,291,42529 Oct 18
MK Capital AB
EntityCompany
Shares1,388,844
Max Pricekr5.25

Ownership Breakdown


Management Team

  • Masoud Khayyami (56yo)

    CEO & Director

    • Tenure: 0yrs
  • Johannes Swartling

    Chief Technology Officer

    • Tenure: 0yrs
  • Mirjam Johansson

    Administrative Manager

    • Tenure: 0yrs
  • Henrik Ljung (61yo)

    Chief Financial Officer

    • Tenure: 0yrs

Board Members

  • Brian Wilson

    Scientific Advisors

    • Tenure: 0yrs
  • Sune Svanberg

    Director

    • Tenure: 0yrs
  • Katarina Svanberg

    Director & Scientific Advisor

    • Tenure: 0yrs
  • Masoud Khayyami (56yo)

    CEO & Director

    • Tenure: 0yrs
  • Steve Hahn

    Scientific Advisor

    • Tenure: 0yrs
  • Ingemar Kihlström (67yo)

    Chairman of the Board

    • Tenure: 0yrs
  • Stefan Andersson-Engels

    Director

    • Tenure: 0yrs
  • Stephen Bown

    Scientific Advisor

    • Tenure: 0yrs
  • Colin Hopper

    Scientific Advisor

    • Tenure: 0yrs
  • Hans Bornefalk

    Director

    • Tenure: 0yrs

Company Information

SpectraCure AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SpectraCure AB (publ)
  • Ticker: SPEC
  • Exchange: OM
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr1.829b
  • Shares outstanding: 81.64m
  • Website: https://www.spectracure.com

Location

  • SpectraCure AB (publ)
  • Magistratsvägen 10
  • Lund
  • Skåne County
  • 226 43
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SPECOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJul 2015
2OKDB (Deutsche Boerse AG)YesShare CapitalDEEURJul 2015

Biography

SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system for the treatment of solid tumor ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 21:39
End of Day Share Price2019/10/22 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.